Samjin Pharmaceutical KRX:005500KOSPI
삼진제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Samjin Pharmaceutical reported revenue of ₩79.6bn, up 6.7% year on year, and operating profit of ₩7.2bn. Samjin Pharmaceutical (삼진제약) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 1 article. It was most often mentioned alongside Chong Kun Dang Pharmaceutical.
Samjin Pharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩79.6bn | +6.7% | ₩7.2bn | ₩6.1bn |
| Q1 2026 | ₩68.1bn | -3.9% | ₩3.6bn | ₩1.4bn |
| Q4 2025 derived | ₩80.5bn | -4.7% | ₩4.2bn | ₩8.9bn |
| Q3 2025 | ₩83.1bn | +3.2% | ₩9.8bn | ₩6.8bn |
| Q2 2025 | ₩74.6bn | +5.5% | ₩8.0bn | ₩4.7bn |
| Q1 2025 | ₩70.9bn | -2.3% | ₩4.8bn | ₩3.7bn |
| Q4 2024 derived | ₩84.5bn | +9.4% | ₩9.2bn | ₩6.9bn |
| Q3 2024 | ₩80.5bn | +12.1% | ₩9.2bn | ₩4.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Samjin Pharmaceutical top stories 2 weeks, by number of outlets
- 1
